Scars Drug Pipeline Analysis Report 2025
Description
Scarring is a common consequence of skin injuries, such as burns, wounds, surgeries, and infections, affecting millions of individuals globally. Approximately 100 million people develop scars from trauma or surgical procedures, with around 15% of these evolving into hypertrophic scars or keloids. There is a significant unmet clinical need for effective therapies, as current treatments, such as silicone gels and corticosteroid injections, often provide limited results. The growing focus on advanced scar management solutions, including gene therapies and novel biologics, is expected to drive the growth of the scars drug pipeline, offering hope for more effective and lasting treatments in the future.
Report Coverage
The Scars Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into scars therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for scars. The scars report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The scars pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with scars treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to scars.
Scars Drug Pipeline Outlook
Scarring occurs naturally as part of the skin's healing process after injuries, such as burns, wounds, surgery, or infections. The body produces collagen to repair damaged tissue, however, sometimes this process results in abnormal scarring, such as hypertrophic scars or keloids. The scars drug pipeline focuses on developing treatments that can regulate collagen production, minimize scarring, and improve skin appearance.
Hypertrophic scars and keloids are treated with therapies like silicone gel sheets, corticosteroid injections, laser therapy, and cryotherapy. Emerging treatments include biologics, gene therapies, and advanced wound dressings that target the underlying mechanisms of scarring for better outcomes. These innovations aim to reduce recurrence and improve aesthetic results for patients.
Scars Epidemiology
The global incidence of scars from skin injuries, including surgery and trauma, affects approximately 100 million people, with 15% progressing to hypertrophic scars or keloids. Keloid formation is most prevalent in individuals of African or Asian descent, with higher visit rates for treatment among these groups. Epidemiological studies indicate a prevalence of 3.5% in African dermatologic patients and a 0.15% annual incidence in Taiwan.
Scars Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of scars drug candidates based on several segmentations, including:
By Phase
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total scars clinical trials.
Scars – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the scars pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and peptide-based therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for scars.
Scars Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR scars drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in scars clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for scars. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of scars drug candidates.
Drug: Elucirem (Gadopiclenol)
The study, sponsored by Johns Hopkins University, aims to evaluate the efficacy of Elucirem (Gadopiclenol) in myocardial scar assessment during cardiac MRI. This Phase 4 study will assess the optimal dose for scar detection and compare Elucirem's performance to standard treatments. The study is expected to be completed by March 2026, with an estimated 10 participants enrolled.
Drug: KP-100LI
The Phase 3 study, sponsored by Kringle Pharma, Inc., aims to evaluate the efficacy and safety of KP-100LI, an intracordal formulation containing recombinant human dHGF, for improving voice function in patients with vocal fold scars. The study is expected to be completed by November 2025 and will involve approximately 62 participants.
Biological: CSB-001 Ophthalmic Solution 0.1%
Claris Biotherapeutics, Inc. is sponsoring a Phase 1 study to assess the safety and efficacy of CSB-001 Ophthalmic Solution 0.1% in individuals with recent corneal scars. The trial, involving 20 participants, began on February 5, 2024, and is expected to conclude by February 28, 2025.
Reasons To Buy This Report
The Scars Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for scars. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within scars pipeline insights.
Key Questions Answered in the Scars – Pipeline Insight Report
Scar Treatment Market
Global Clinical Trials Market
Report Coverage
The Scars Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into scars therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for scars. The scars report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The scars pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with scars treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to scars.
Scars Drug Pipeline Outlook
Scarring occurs naturally as part of the skin's healing process after injuries, such as burns, wounds, surgery, or infections. The body produces collagen to repair damaged tissue, however, sometimes this process results in abnormal scarring, such as hypertrophic scars or keloids. The scars drug pipeline focuses on developing treatments that can regulate collagen production, minimize scarring, and improve skin appearance.
Hypertrophic scars and keloids are treated with therapies like silicone gel sheets, corticosteroid injections, laser therapy, and cryotherapy. Emerging treatments include biologics, gene therapies, and advanced wound dressings that target the underlying mechanisms of scarring for better outcomes. These innovations aim to reduce recurrence and improve aesthetic results for patients.
Scars Epidemiology
The global incidence of scars from skin injuries, including surgery and trauma, affects approximately 100 million people, with 15% progressing to hypertrophic scars or keloids. Keloid formation is most prevalent in individuals of African or Asian descent, with higher visit rates for treatment among these groups. Epidemiological studies indicate a prevalence of 3.5% in African dermatologic patients and a 0.15% annual incidence in Taiwan.
Scars Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of scars drug candidates based on several segmentations, including:
By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptide-Based Therapies
- Oral
- Parenteral
- Others
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis , phase II covers a major share of the total scars clinical trials.
Scars – Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the scars pipeline analysis include small molecules, monoclonal antibodies, gene therapies, and peptide-based therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for scars.
Scars Clinical Trials Therapeutic Assessment – Competitive Dynamics
The EMR scars drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in scars clinical trials:
- AbbVie
- Innovo Therapeutics, Inc.
- Claris Biotherapeutics, Inc.
- Scarless Laboratories, Inc.
- Kringle Pharma, Inc.
- MedRegen LLC.
- Rejoni Inc.
- Takeda Pharmaceuticals
- Smith & Nephew plc.
- Bausch Health
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for scars. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of scars drug candidates.
Drug: Elucirem (Gadopiclenol)
The study, sponsored by Johns Hopkins University, aims to evaluate the efficacy of Elucirem (Gadopiclenol) in myocardial scar assessment during cardiac MRI. This Phase 4 study will assess the optimal dose for scar detection and compare Elucirem's performance to standard treatments. The study is expected to be completed by March 2026, with an estimated 10 participants enrolled.
Drug: KP-100LI
The Phase 3 study, sponsored by Kringle Pharma, Inc., aims to evaluate the efficacy and safety of KP-100LI, an intracordal formulation containing recombinant human dHGF, for improving voice function in patients with vocal fold scars. The study is expected to be completed by November 2025 and will involve approximately 62 participants.
Biological: CSB-001 Ophthalmic Solution 0.1%
Claris Biotherapeutics, Inc. is sponsoring a Phase 1 study to assess the safety and efficacy of CSB-001 Ophthalmic Solution 0.1% in individuals with recent corneal scars. The trial, involving 20 participants, began on February 5, 2024, and is expected to conclude by February 28, 2025.
Reasons To Buy This Report
The Scars Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for scars. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within scars pipeline insights.
Key Questions Answered in the Scars – Pipeline Insight Report
- What is the current landscape of scars pipeline drugs?
- Which companies/institutions are developing scars emerging drugs?
- How many phase II drugs are currently present in scars pipeline drugs?
- Which company is leading the scars pipeline development activities?
- What is the current scars therapeutic assessment?
- What are the opportunities and challenges present in the scars drug pipeline landscape?
- What is the efficacy and safety profile of scars pipeline drugs?
- Which companies/institutions are involved in scars collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in scars?
Scar Treatment Market
Global Clinical Trials Market
Table of Contents
200 Pages
- 1 Preface
- 1.1 Introduction
- 1.2 Objectives of the Study
- 1.3 Research Methodology & Assumptions
- 2 Executive Summary
- 3 Overview of Scars
- 3.1 Signs and Symptoms
- 3.2 Causes
- 3.3 Risk Factors
- 3.4 Diagnosis
- 3.5 Treatment
- 4 Patient Profile: Scars
- 4.1 Patient Profile Overview
- 4.2 Patient Psychology and Emotional Impact Factors
- 4.3 Risk Assessment and Treatment Success Rate
- 5 Scars: Epidemiology Snapshot
- 5.1 Scars Incidence by Key Markets
- 5.2 Scars – Patients Seeking Treatment in Key Markets
- 6 Scars: Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 7 Scars: Key Facts Covered
- 7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
- 7.2 Top Countries Contributing to Clinical Trials in Europe
- 7.3 Top Countries Contributing to Clinical Trials in North America
- 7.4 Top Countries Contributing to Clinical Trials in Other Regions
- 8 Scars, Drug Pipeline Assessment
- 8.1 Assessment by Treatment Type
- 8.2 Assessment by Route of Administration
- 8.3 Assessment by Drug Class
- 9 EMR Drug Pipeline Comparative Analysis
- 9.1 List of Scars Pipeline Drugs
- 9.1.1 By Company
- 9.1.2 By Phase
- 9.1.3 By Indication
- 9.1.4 By Trial Status
- 9.1.5 By Funder Type
- 9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
- 10 Scars Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
- 10.1 Comparative Analysis for Late-Stage Drugs
- 10.1.1 Study Type
- 10.1.2 Recruitment Status
- 10.1.3 Company
- 10.1.4 Funder Type
- 10.2 Product Level Analysis*
- 10.2.1 Drug: KP-100LI
- 10.2.1.1 Product Description
- 10.2.1.2 Trial ID
- 10.2.1.3 Sponsor Name
- 10.2.1.4 Study Type
- 10.2.1.5 Drug Class
- 10.2.1.6 Eligibility Criteria
- 10.2.1.7 Study Record Dates
- 10.2.1.7.1 First Submitted
- 10.2.1.7.2 First Posted
- 10.2.1.7.3 Last Update Posted
- 10.2.1.7.4 Last Verified
- 10.2.1.8 Indication
- 10.2.1.9 Study Design
- 10.2.1.10 Recruitment Status
- 10.2.1.11 Enrollment (Estimated)
- 10.2.1.12 Location Countries
- 10.2.1.13 Recent Results
- 10.2.2 Other Drugs
- 11 Scars Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
- 11.1 Comparative Analysis for Mid-Stage Drugs
- 11.1.1 Study Type
- 11.1.2 Recruitment Status
- 11.1.3 Company
- 11.1.4 Funder Type
- 11.2 Product Level Analysis*
- 11.2.1 Biological: CSB-001 Ophthalmic Solution 0.1%
- 11.2.1.1 Product Description
- 11.2.1.2 Trial ID
- 11.2.1.3 Sponsor Name
- 11.2.1.4 Study Type
- 11.2.1.5 Drug Class
- 11.2.1.6 Eligibility Criteria
- 11.2.1.7 Study Record Dates
- 11.2.1.7.1 First Submitted
- 11.2.1.7.2 First Posted
- 11.2.1.7.3 Last Update Posted
- 11.2.1.7.4 Last Verified
- 11.2.1.8 Indication
- 11.2.1.9 Study Design
- 11.2.1.10 Recruitment Status
- 11.2.1.11 Enrollment (Estimated)
- 11.2.1.12 Location Countries
- 11.2.1.13 Recent Results
- 11.2.2 Drug: Botulinum toxin type A
- 11.2.3 Other Drugs
- 12 Scars Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
- 12.1 Comparative Analysis for Early-Stage Drugs
- 12.1.1 Study Type
- 12.1.2 Recruitment Status
- 12.1.3 Company
- 12.1.4 Funder Type
- 12.2 Product Level Analysis*
- 12.2.1 Biological: CSB-001 Ophthalmic Solution 0.1%
- 12.2.1.1 Product Description
- 12.2.1.2 Trial ID
- 12.2.1.3 Sponsor Name
- 12.2.1.4 Study Type
- 12.2.1.5 Drug Class
- 12.2.1.6 Eligibility Criteria
- 12.2.1.7 Study Record Dates
- 12.2.1.7.1 First Submitted
- 12.2.1.7.2 First Posted
- 12.2.1.7.3 Last Update Posted
- 12.2.1.7.4 Last Verified
- 12.2.1.8 Indication
- 12.2.1.9 Study Design
- 12.2.1.10 Recruitment Status
- 12.2.1.11 Enrollment (Estimated)
- 12.2.1.12 Location Countries
- 12.2.2 Other Drugs
- 13 Scars Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
- 13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
- 13.1.1 Study Type
- 13.1.2 Recruitment Status
- 13.1.3 Company
- 13.1.4 Funder Type
- 13.2 Product Level Analysis*
- 13.2.1 Drug 1
- 13.2.1.1 Product Description
- 13.2.1.2 Trial ID
- 13.2.1.3 Sponsor Name
- 13.2.1.4 Study Type
- 13.2.1.5 Drug Class
- 13.2.1.6 Eligibility Criteria
- 13.2.1.7 Study Record Dates
- 13.2.1.7.1 First Submitted
- 13.2.1.7.2 First Posted
- 13.2.1.7.3 Last Update Posted
- 13.2.1.7.4 Last Verified
- 13.2.1.8 Indication
- 13.2.1.9 Study Design
- 13.2.1.10 Recruitment Status
- 13.2.1.11 Enrollment (Estimated)
- 13.2.1.12 Location Countries
- 13.2.2 Other Drugs
- 14 Scars, Key Drug Pipeline Companies
- 14.1 AbbVie
- 14.1.1 Company Snapshot
- 14.1.2 Pipeline Product Portfolio
- 14.1.3 Financial Analysis
- 14.1.4 Recent News and Developments
- 14.2 Innovo Therapeutics, Inc.
- 14.2.1 Company Snapshot
- 14.2.2 Pipeline Product Portfolio
- 14.2.3 Financial Analysis
- 14.2.4 Recent News and Developments
- 14.3 Claris Biotherapeutics, Inc.
- 14.3.1 Company Snapshot
- 14.3.2 Pipeline Product Portfolio
- 14.3.3 Financial Analysis
- 14.3.4 Recent News and Developments
- 14.4 Scarless Laboratories, Inc.
- 14.4.1 Company Snapshot
- 14.4.2 Pipeline Product Portfolio
- 14.4.3 Financial Analysis
- 14.4.4 Recent News and Developments
- 14.5 Kringle Pharma, Inc.
- 14.5.1 Company Snapshot
- 14.5.2 Pipeline Product Portfolio
- 14.5.3 Financial Analysis
- 14.5.4 Recent News and Developments
- 14.6 MedRegen LLC.
- 14.6.1 Company Snapshot
- 14.6.2 Pipeline Product Portfolio
- 14.6.3 Financial Analysis
- 14.6.4 Recent News and Developments
- 14.7 Rejoni Inc.
- 14.7.1 Company Snapshot
- 14.7.2 Pipeline Product Portfolio
- 14.7.3 Financial Analysis
- 14.7.4 Recent News and Developments
- 14.8 Takeda Pharmaceuticals
- 14.8.1 Company Snapshot
- 14.8.2 Pipeline Product Portfolio
- 14.8.3 Financial Analysis
- 14.8.4 Recent News and Developments
- 14.9 Smith & Nephew plc.
- 14.9.1 Company Snapshot
- 14.9.2 Pipeline Product Portfolio
- 14.9.3 Financial Analysis
- 14.9.4 Recent News and Developments
- 14.10 Bausch Health
- 14.10.1 Company Snapshot
- 14.10.2 Pipeline Product Portfolio
- 14.10.3 Financial Analysis
- 14.10.4 Recent News and Developments
- 15 Regulatory Framework for Drug Approval, By Region
- 16 Terminated or Suspended Pipeline Products
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
